Understanding Closed-Loop Systems (AID)
How Automated Insulin Delivery systems work, their clinical benefits, and what they still require from the user.
A "Closed-Loop" system, medically referred to as Automated Insulin Delivery (AID), is the current standard of care for intensive Type 1 Diabetes management. It represents the closest technology has come to an artificial pancreas.
How It Works
An AID system requires three components working together in a loop:
- The Sensor (CGM): Reads interstitial glucose levels continuously.
- The Algorithm: Software that analyzes the CGM data to predict where blood sugar will be in 30 to 60 minutes.
- The Pump: The hardware that physically delivers the insulin based on the algorithm's commands.
Why "Hybrid" Closed-Loop?
Current commercial systems (Omnipod 5, Tandem Control-IQ, Medtronic SmartGuard) are actually hybrid closed-loop systems. This means they are not fully autonomous.
What the system does automatically: Adjusts background (basal) insulin to keep you steady overnight, corrects minor highs, and suspends insulin to prevent severe lows.
What you must still do manually: Count carbohydrates and command the pump to deliver a bolus for meals. Rapid-acting insulin still takes 15-20 minutes to start working; current algorithms cannot react fast enough to a meal spike without manual intervention.
Clinical Outcomes
Pivotal trials for major AID systems consistently show that switching from Multiple Daily Injections (MDI) to an AID system results in:
- Increased Time in Range (TIR): An average increase of 11% to 15% (equivalent to 2.5 to 3.5 more hours per day in the 70-180 mg/dL target range).
- Reduced HbA1c: Typical reductions of 0.3% to 0.5%.
- Reduced Hypoglycemia: Significant reductions in time spent below 70 mg/dL, largely due to the system's ability to suspend insulin delivery before a low occurs.
- Improved Sleep: Because the algorithm works overnight to flatten glucose lines, users experience fewer overnight alarms and better sleep quality.